SCHEMBL3660419

SCHEMBL3660419

O=C(O)CCNCCC(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.56
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
LTA4H P09960 4/20 0.51
S1PR1 P21453 4/20 0.50
S1PR3 Q99500 2/20 0.50
S1PR5 Q9H228 1/20 0.48
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 2/20 0.47
KMT2A Q03164 2/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
CPB1 P15086 1/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13323438 0.95 ALDH1A1 (0.61) HTTALDH1A1MAPK1L3MBTL1LTA4H
SCHEMBL7378770 0.89 CA1 (0.58) HTTALDH1A1MAPK1L3MBTL1LTA4H
SCHEMBL24984042 0.89 ALDH1A1 (0.54) HTTALDH1A1MAPK1L3MBTL1LTA4H
SCHEMBL18515898 0.87 ALDH1A1 (0.53) HTTALDH1A1MAPK1L3MBTL1LTA4H
SCHEMBL17177605 0.87 ALDH1A1 (0.53) HTTALDH1A1MAPK1L3MBTL1LTA4H
SCHEMBL16791126 0.87 ALDH1A1 (0.53) HTTALDH1A1MAPK1L3MBTL1LTA4H
SCHEMBL4169984 0.87 CCR6 (0.57) HTTALDH1A1MAPK1L3MBTL1LMNA
SCHEMBL24119984 0.87 ALDH1A1 (0.56) HTTALDH1A1MAPK1L3MBTL1LTA4H
SCHEMBL1627692 0.86 ALDH1A1 (0.51) HTTALDH1A1MAPK1L3MBTL1LTA4H
Hydrochloric Acid SCHEMBL27352426 0.85 CCR6 (0.56) HTTALDH1A1MAPK1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217621-B1 INSULIN DERIVATIVE NOVO NORDISK AS (DK) 2015-04-22 EP disclosed
US-8710000-B2 Insulin derivative NOVO NORDISK A/S (DK) 2014-04-29 US disclosed
US-20100279931-A1 Insulin Derivative NOVO NORDISK A/S 2010-11-04 US disclosed
EP-2217621-A1 INSULIN DERIVATIVE Novo Nordisk A/S (DK) 2010-08-18 EP disclosed
WO-2009060071-A1 INSULIN DERIVATIVE NOVO NORDISK A/S (DK) 2009-05-14 WO disclosed
EP-2058330-A1 Insulin derivative NOVO NORDISK A/S (DK) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279931-A1 Insulin Derivative IAPP, INSR, GPR119 HTT 1328/4885ALDH1A1 3984/4885MAPK1 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.